Roche: GA101 progresses on its journey

NEUTRAL, Fair Value CHF202 (+2%)

News published on January Thursday 31, 2013
Share on
Roche today announced that GA101 (obinutuzumab) has met its primary endpoint in the first stage of the CLL11 phase III study which compared the combination of the drug with chlorambucil against chlorambucil alone on PFS.

Full report available to subscribers
Please contact marketing@bryangarnier.fr

The Essentials

Everything you need to know about investment banking dedicated to growth
Stay Informed
Get our news
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities